GPC Biotech AG (Frankfurt Stock Exchange: GPC) today announced that the Company will hold an analyst and press meeting in Frankfurt, Germany to discuss financial results for the fiscal year 2008 and to provide a business update.

The meeting, which will be conducted in English, will be held Wednesday, March 25, 2009 at 14:00 CET/9:00 AM EST in Frankfurt.

The meeting will also be accessible via telephone or webcast. The live webcast, including synchronized slides, will be available on the GPC Biotech Web site at www.gpc-biotech.com. A replay will be available via the Web site following the live event.

Dial-in numbers for the analyst and press meeting are as follows:

Please dial in 10 minutes before the beginning of the meeting.

About GPC Biotech

GPC Biotech AG is a publicly traded biopharmaceutical company focused on developing anti-cancer drugs. The Company currently has two programs in clinical development: satraplatin, an oral platinum compound and RGB-286638, a multi-targeted protein kinase inhibitor. On February 18, 2009 the Company announced plans to combine its business with U.S.-based Agennix, Incorporated in a new German company. Agennix, a privately-held biotechnology company, is developing oral talactoferrin, a product candidate that is currently in Phase 3 trials for non-small cell lung cancer. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at www.gpc-biotech.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech AG, including those relating to the proposed combination of the Company’s business with Agennix in a new German company. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future outcomes to differ significantly from the outcomes expressed or implied by such forward-looking statements. Actual outcomes could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. We direct you to GPC Biotech’s Annual Report on Form 20-F for the fiscal year ended December 31, 2007 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

GPC Biotech AG
Investor Relations & Corporate Communications
+49 (0)89 8565-2693
ir@gpc-biotech.com
or
In the U.S.:
Laurie Doyle, +1 609-524-5884
Director, Investor Relations & Corporate Communications
usinvestors@gpc-biotech.com
or
Additional media contacts for Europe:
MC Services AG
+49 (0) 89 210 228 0
Raimund Gabriel
raimund.gabriel@mc-services.eu
or
Hilda Juhasz
hilda.juhasz@mc-services.eu
or
Additional investor contact for Europe:
Trout International LLC
Lauren Rigg, Vice President, +44 207 936 9325
lrigg@troutgroup.com